Moderna announces first patient dosed in Phase 1/2 study of mRNA-2808

Moderna (MRNA) announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational mRNA-based T-cell engager for participants with relapsed or refractory multiple myeloma. The first dose was administered at SCRI Oncology Partners in Nashville, Tennessee, in collaboration with Sarah Cannon Research Institute. mRNA-2808 is an investigational, multiplexed therapy that encodes three TCEs that target three validated myeloma-associated antigens. This novel strategy aims to address tumor heterogeneity and overcome known mechanisms of target-mediated resistance.